top of page
Clinical Milestone

First-in-Human Experience

Vicora recently completed its initial First-in-Human experience evaluating the Vibrato platform in patients requiring mechanical thrombectomy. Early findings demonstrated substantial reductions in RV/LV ratio and thrombus burden with no reported major adverse events.

Study Overview

Location: Kraków, Poland

Site: Saint John Paul II – Kraków Specialist Hospital

Principal Investigators: Prof. Grzegorz Kopec & Dr. Jakub Stepniewski

Primary Safety Endpoint

Major Adverse Events within 48-hours: 

  • Death

  • Major Bleeding

  • Device-related Adverse Events

Primary Efficacy Endpoint

Reduction in RV/LV Ratio from baseline to 48-hours or discharge by CT angiography

Improvement in RV/LV Ratio

RVLV.png

*Based on the current enrollment of 4 patients

​

  • Clinical Deterioration

  • Pulmonary Vascular Injury

  • Cardiac Injury

Reduction in Refined Modified Miller Score

RMSI.png

0 

0 

0 

Reported Transfusions or Reinterventions

MAEs Reported at 48h & 30-days

Patient Stays in the ICU

bottom of page